Direct Compression Behavior of Compacted Azithromycin Dihydrate on High-Speed Rotary Presses

Compacted azithromycin dihydrate intended for direct compression is typically specified with a D(90) of 180–250 µm, a bulk density of 0.45–0.60 g/mL, and a tapped density that yields a Carr index between 20% and 28% when measured according to USP <616> and Ph.Eur. 2.9.36. The narrow particle size distribution reduces the segregation potential between the API and coarse direct-compression excipients such as spray-dried lactose monohydrate and microcrystalline cellulose, but the formulation still requires verification of blend uniformity at hopper low-level conditions because the compacted particles have a higher density than many lactose grades and can stratify during bin transfer. In a standard direct-compression formula, azithromycin dihydrate represents approximately 30–60% w/w of the total core mass, with microcrystalline cellulose and lactose monohydrate serving as the dominant compressible diluents, croscarmellose sodium at 2–4% w/w as the superdisintegrant, colloidal silicon dioxide at 0.5–1.0% w/w as a glidant, and magnesium stearate at 0.5–1.0% w/w as the final lubricant; magnesium stearate blending should be maintained below 5 min because the hydrophobic film it deposits on the compacted API surface can retard dissolution in pH 6.0 phosphate buffer. On a Korsch XL 400 or Fette 2090i rotary press, main compression force is generally held between 8 kN and 16 kN, with precompression force between 3 kN and 5 kN and turret speed from 40 rpm to 70 rpm for a 10 mm round standard concave tooling set; operation above 18 kN has been associated with capping because the compacted dihydrate particles exhibit elastic recovery after their yield pressure is exceeded, and the resulting expansion stress at the band edge is not absorbed by brittle excipients such as anhydrous dibasic calcium phosphate. Tablet friability is evaluated according to USP <1216> with an acceptance criterion of not more than 0.8%, disintegration according to USP <701> in water at 37 °C with a typical limit of not more than 30 min, and dissolution according to USP <711> apparatus II at 50 rpm using 900 mL of buffered medium; the Q value and sampling time are product-specific and must be taken from the approved regulatory file rather than inferred from the API monograph. The main operational boundary for direct compression is that the compacted grade absorbs moisture more slowly than unmodified azithromycin powder, but storage of open containers in relative humidity above 60% can reduce flow and increase sticking to punch faces; therefore, the powder should be discharged only in a controlled environment and returned to airtight containers immediately after weighing.

What Limits Fill Weight Variation in Automated Capsule Operations?

Fill weight variability in automatic capsule machines originates primarily from inconsistent bulk density in the hopper, excessive powder bed compression in the dosing disc, and flow interruptions caused by the cohesive fraction of the compacted API. On a Bosch GKF 1400 or an MG2 Planeta dosator equipped with a dosing disc, the compacted/micro azithromycin dihydrate grade is expected to flow without punch sticking when Hausner ratio remains below 1.35 and the flow function coefficient measured by shear cell is above 4; however, lot-to-lot variation in residual fines from upstream milling can shift the Hausner ratio toward 1.40, producing variable tamping pin penetration and weight variability above ±5%. The dosing disc speed should be matched to the powder flow, with common operating windows between 60 cycles/min and 120 cycles/min, tamping pin compression force from 0.5 kN to 1.5 kN, and a powder bed height maintained at not less than 30 cm; a starved hopper causes the auger-assisted feed to deliver non-representative particle fractions because the compacted dense particles compact further under their own mass in the lower hopper cone. Azithromycin capsules are typically filled into size 0 or size 1 hard gelatin or HPMC shells depending on the fill weight and the selected diluent; content uniformity is assessed by USP <905> and weight variation should be evaluated concurrently because weight variation alone cannot detect preferential loss of the API from a coarser excipient fraction. Lubrication is critical: a final lubricant addition of 0.5–1.0% w/w magnesium stearate with 2–4 min of tumble blending reduces die wall friction and ensures consistent plug formation in dosator systems, but extended blending beyond 10 min should be avoided because the same lubricant suppresses wetting of the compacted API and delays release in pH 6.0 dissolution media. Automated checkweighing on a H&K or equivalent capsule checkweigher is recommended for high-speed lines because it rejects units outside the set weight band before they enter the metal detector.

The manufacture of dry powder oral suspension sachets from azithromycin dihydrate compacted/micro grade requires a deliberately broad granule size distribution after wet massing and a buffered vehicle because the API has an intensely bitter taste and pH-dependent solubility. A high-shear granulation step is often used to bind the API with a taste-masking polymer; if the active is not fully entrapped, free azithromycin on the granule surface releases immediately in the mouth during reconstitution and causes patient refusal. The binder solution may contain hypromellose or an aqueous ethylcellulose dispersion, with binder concentration between 3% w/w and 6% w/w, and the wet mass is discharged at a target loss on drying of 1.5–2.5% after drying in a fluid-bed dryer such as a Glatt GPCG 3 or in tray ovens for small batches. Drying should maintain product temperature not above 35 °C for the dihydrate form because higher temperatures can accelerate the release of bound water and alter the crystal lattice sufficiently to shift dissolution; the final moisture value is confirmed by USP <731> or Karl Fischer USP <921> method Ia, and the granule is sieved through a 1.0 mm screen with the oversize milled at low speed to avoid generating fines below 75 µm. Sachet filling lines must accommodate granular material with bulk density 0.50–0.65 g/mL, and fill weight variation is controlled at ±5% using volumetric cup fillers or auger fillers; the sachet seal integrity is verified by visual inspection and dye leak tests after sealing, with a minimum seal strength sufficient to survive distribution. The reconstituted suspension should be evaluated for pH, viscosity, and sedimentation volume at 25 °C and 5 °C because the buffered vehicle used to suppress the bitter taste can interact with the API and shift the pH outside the intended range of the approved product. Stability protocols include ICH Q1A storage at 25 °C/60% RH and 40 °C/75% RH with moisture-proof sachet laminates, and published data for this specific configuration is limited to the granule formulation under evaluation because the buffer capacity and polymer ratio are product-specific.

When the API Particle Size Is Reduced Below 20 µm for Lyophilized Injectables

Injectable-grade azithromycin dihydrate presents two critical boundary conditions: low aqueous solubility at neutral pH and the requirement for sterility assurance without damaging the molecule. The buffered formulation is commonly produced by reacting azithromycin dihydrate with citric acid in water for injection, forming a soluble citrate salt; the resulting solution is adjusted to the target pH with sodium hydroxide and filtered through a 0.22 µm sterilizing-grade PVDF or PES membrane. Terminal steam sterilization is generally unsuitable because the citrate-buffered solution and the API can degrade at autoclave temperatures, so aseptic filtration followed by lyophilization is the standard manufacturing route. For a lyophilized injectable, the particle size of the incoming API is less important than the dissolution profile of the citrate salt, but a micronized or compacted/micro grade with a D(90) below 20 µm shortens the wetting and solution preparation time when the API is charged into the cGMP reactor; the solution should be checked for undissolved particulate before filtration. The lyophilization cycle on a Lyostar II or equivalent should freeze the filled vials to a shelf temperature of −45 °C for at least 2 h, with primary drying at shelf temperature −25 °C to −15 °C and chamber pressure 80–150 µbar, followed by secondary drying at 25–30 °C until the moisture content by Karl Fischer is below the product-specific limit; the resulting cake should be uniform, free of melt-back and shrinkage, and the residual moisture must be controlled to avoid hydrolysis of the macrolide lactone ring. Endotoxin is tested by USP <85> with a limit commonly set at <0.5 EU/mg for parenteral azithromycin, sterility by USP <71>, particulate matter by USP <790> for subvisible particles, and visible particles by light obscuration; environmental monitoring of the aseptic filling line is performed under ISO 14644-1 class 5 with appropriate gowning and disinfection controls under 21 CFR 211.67 and 21 CFR 211.113. Because the lyophilized cake is hygroscopic, the vials must be sealed under dry nitrogen or vacuum and the stopper moisture vapor transmission rate must be verified to prevent moisture ingress during storage; published data for terminal heat sterilization of azithromycin citrate is limited, and aseptic processing remains the conservative regulatory expectation unless a manufacturer submits a validated alternative to the applicable authority.

Because the compacted grade has a higher individual particle density than spray-dried lactose and mannitol, blend segregation in transfer lines and compression feed frames is a latent failure mode that is less visible than poor flow but produces content uniformity failure at the end of a long campaign. Vacuum transfer of the final blend should be configured with minimal vertical drop and a receiving hopper vented to avoid density-driven elutriation of the fine API fraction; sampling across the discharge stream is performed according to 21 CFR 211.110 and content uniformity by USP <905>. The blend bulk density should be measured at the beginning, middle, and end of the compression run, and a change in Carr index of more than 5 percentage points from the qualified range should trigger an in-process investigation because it indicates particle reordering in the hopper or over-lubrication. When the direct compression input is replaced with the compacted/micro grade in a product previously manufactured with a milled powder, the addition ratio of colloidal silicon dioxide may need to be reduced from 1.0% w/w to 0.5% w/w because the denser API has a lower surface area per unit volume and the glidant can settle into the void spaces of the blend rather than coating the hopper wall. Such an adjustment must be supported by a full factorial or central composite design examining blend flow, tablet hardness, disintegration, and dissolution, with the resulting design space filed as a post-approval change under the applicable regulatory pathway.

In Fluidized-Bed Wet Granulation, Moisture Mass Balance Governs Granule Hardness

For granules intended for oral suspension or dispersible tablets, fluidized-bed wet granulation has a narrow process window because over-wetting causes defluidization and undermixing, while under-wetting produces friable granules that shatter during sachet filling. The spray solution may be an aqueous dispersion or solution of a binder such as hypromellose or povidone at 3–6% w/w, sprayed through a top-spray nozzle with atomizing air pressure 1.0–1.5 bar; product temperature is maintained at 28–32 °C by adjusting inlet air temperature between 55 °C and 65 °C, and the inlet air dew point should be kept below 8 g/kg to avoid condensation and localized over-wetting. The moisture content of the finished granule exerts a direct effect on granule hardness, friability, and flow, and the Karl Fischer value is specified at 1.5–2.5% before final blending; granules dried below 1.0% may become brittle and generate fines, while granules above 3.0% may cake during holding prior to sachet filling or tableting. Particle size distribution after sieving is controlled with the oversize fraction not more than 10% retained on a 1.0 mm sieve and the fine fraction below 75 µm not exceeding 20%, because the API is added as the compacted/micro grade and excessive fines create sticking on the rotary press or inconsistent cup filling. The granule bulk density should fall within 0.50–0.65 g/mL to permit reproducible volumetric filling; if the density is below this range, the fill weight becomes sensitive to vibration and sachet headspace, and if the density is above this range, the granule may compact in the filling hopper and increase fill weight drift. Process analytical technology may include near-infrared moisture monitoring at the dryer outlet, but it does not replace the reference method of USP <731> or USP <921> for release. In a dispersible tablet formulation, wet granulation is followed by drying, milling, lubrication, and compression on a rotary press at 8–14 kN; disintegration of the dispersible tablet is assessed according to USP <701> in water at 37 °C, with a typical limit of not more than 3 min for the dispersed form, and dissolution is performed according to USP <711> in pH 6.0 phosphate buffer. The operational boundary is that azithromycin dihydrate should not be exposed to prolonged wet massing in strongly alkaline granulating fluid, because the macrolide lactone is susceptible to base-catalyzed hydrolysis, and the maximum kneading time for a high-shear route should be established experimentally using related substances testing rather than assumed from other macrolide antibiotics.